Related references
Note: Only part of the references are listed.Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
Maria Roed Skarderud et al.
CANCER TREATMENT REVIEWS (2018)
NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Identification of a novel RASD1 somatic mutation in a USP8-mutated corticotroph adenoma
Andrew Uzilov et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Robert P. Jones et al.
BRITISH JOURNAL OF CANCER (2017)
Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
Erika Martinelli et al.
CANCER TREATMENT REVIEWS (2017)
Mutation spectra of RAS gene family in colorectal cancer
Yu-Yao Chang et al.
AMERICAN JOURNAL OF SURGERY (2016)
The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
Hae Su Kim et al.
BMC CANCER (2016)
dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs
Xiaoming Liu et al.
HUMAN MUTATION (2016)
Functional exploration of colorectal cancer genomes using Drosophila
Erdem Bangi et al.
NATURE COMMUNICATIONS (2016)
RAS and BRAF in metastatic colorectal cancer management
Jun Gong et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Value of bevacizumab in treatment of colorectal cancer: A meta-analysis
Chun-Ying Qu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
Sang Min Lim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Mutational Analysis and Clinical Correlation of Metastatic Colorectal Cancer
Andrea L. Russo et al.
CANCER (2014)
Combining Genetic Perturbations and Proteomics to Examine Kinase-Phosphatase Networks in Drosophila Embryos
Richelle Sopko et al.
DEVELOPMENTAL CELL (2014)
A general framework for estimating the relative pathogenicity of human genetic variants
Martin Kircher et al.
NATURE GENETICS (2014)
Bisphosphonates inactivate human EGFRs to exert antitumor actions
Tony Yuen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Incidence and Prognostic Impact of KRAS and BRAF Mutation in Patients Undergoing Liver Surgery for Colorectal Metastases
Georgios Karagkounis et al.
CANCER (2013)
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
Emanuele Valtorta et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability
Yuzo Umeda et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
Ting Deng et al.
MEDICAL ONCOLOGY (2013)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study
M. Pazianas et al.
OSTEOPOROSIS INTERNATIONAL (2012)
VEGF Inhibition, Hypertension, and Renal Toxicity
Suzanne R. Hayman et al.
CURRENT ONCOLOGY REPORTS (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Use of Bisphosphonates and Reduced Risk of Colorectal Cancer
Gad Rennert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A genome-scale shRNA resource for transgenic RNAi in Drosophila
Jian-Quan Ni et al.
NATURE METHODS (2011)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib
Michael J. Donovan et al.
EUROPEAN JOURNAL OF CANCER (2009)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension
Hassane Izzedine et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
Panagiotis A. Konstantinopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
An optimized transgenesis system for Drosophila using germ-line-specific φC31 integrases
Johannes Bischof et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
An accurate and interpretable model for siRNA efficacy prediction
Jean-Philippe Vert et al.
BMC BIOINFORMATICS (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
G Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention
HB Mo et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2004)
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis
WWL Wong et al.
LEUKEMIA (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
